PatientView has released a cut of their 2025 data on 505 global cancer-related patient associations. This data shows a patient population that respects the work being done on these conditions, but that globally has issues regarding pricing and access. 

Patient associations that gave pharma a rating of "excellent" or "good" in the following areas:

It really shows how patients respect the products but are often frustrated at difficult access due to pricing.

Looking at trends since 2021, we see that the values remain relatively consistent.

For a longer trends you can see our review of the company's general reputation press release. We charted that data back to 2014 based on historical releases.

MM+M reports on Klick's recent acquisition of Oxford PharmaGenesis, a UK-based health science communications consultancy founded only one year after Klick (1998 vs. 1997). 

Some stats on the combined reach:

See also the Klick press release.

* Superchargers provide instant power and torque because they are driven by the engine's crankshaft while turbos are driven by exhaust gasses so introduce "turbo lag. Source: years of wrenching, and Hagerty (no personal footnotes -Ed.)

Biopharma mega-rounds have edged out 2025 with a super-mega deal ($2.1 billion) in May.

Endpoints marked the deals with a China connection to highlight the amount of activity now there.

The authors also broke out investment by condition. Autoimmune and Oncology round to the same amount at one decimal place with the former technically ahead.

Less than half of Americans feel secure in their ability to pay for healthcare. This skews younger for those entering the workforce or with less experience.

This matters to pharma, which is one of the four top "blame centers" for cost (insurance, providers, PBMs, and pharma). The report from Gallup shows 51% feel secure about healthcare services, and only 42% about pharmaceuticals.

When looking at this data by condition, the top two for cost insecurity are mental health related (anxiety and depression) though all conditions are within a 10% band.

Amazon's Prime "Day," which now extends over four days, always shows strong sales as consumers look for deals mid-year. This year grew 9.3% to $26.4 billion. We created a running tally of growth last year and we've updated it:

Amazon's top categories for this year started with electronics and appliances as big items get big discounts.

For the health category, however, the smartwatch made a good showing. 

Affiliates and partners, which includes influencers but isn't exclusively them, drove over one-fifth of the total revenues for Prime Day. It also has 3x the "add to cart" effects for shoppers. Or, perhaps, it's easier to track affiliate links than social sources (no conspiracy theories -Ed.).

Haleon, a company that I just found out makes six of my favorite OTC health products (no personal stories -Ed.), has partnered with Microsoft to help it integrate AI into its business operations.

As companies integrate AI into business functions it becomes hard to tell what efficiencies come from the people, the processes, or AI itself. Since consistent business metrics were already hard to come by, proving ROI for tokens spent can be difficult.

Here are other health + AI related partnerships from the Fierce story:

Anthropic last week released Claude Science, an AI suite of tools to help scientists manage research workflows, combine literature reviews, research coding, data analysis and visualization, manuscript drafting, and reproducibility checks.

The toolset is custom-made for life sciences R&D with integrations to tools like PubMed, Jupyter, R, remote compute, and scientific databases. In essence, Anthropic is trying to build out an IDE (integrated development environment) for biotech that competes with existing solutions by integrating agentic AI directly into the workbench.

A study published in the Journal of the American Heart Association performed a meta analysis on smartphone and wearable health interventions. The study found positive results from the technologies.

Perhaps the most direct evidence was an average of just under 1,100 additional steps per day with considerable variation by study.

The behavioral change techniques that the researchers categorized were varied but the top ones were:

By the end of last year roughly half of all video views on TikTok and Instagram were from non-followers.

Not only did Dash see more videos being watch, but they were being watched for slightly longer. The watch times rose to 8 seconds for Instagram and 7.2 for TikTok.

For the increases in videos watched, the numbers rose for both platforms. However, Dash presented the data in a strange way that accentuated the difference between the platforms (bottom). Note the scale they used. We recharted it (top) to show the actual ratio.

The above data is over a two-year period of 2023 to 2025. Even so, more of anything in the saturated social landscape is impressive.

Regardless of the visual shenanigans, it's obvious that 44% more views on TikTok is substantial. This data is from before the ownership change in January of this year.

Emarketer had a pair of charts last week that showed app retention at day two and at day 30. For both charts health apps are just below financial in the number two slot.

Financial apps are by far the winners in stickiness, but 11% of health apps are still being opened 30 days after install. 

Per the title of this story, however, our advice is generally "don't build one." Pharma typically does not have a use-case that warrants a full app on the patient's smartphone. Better is to partner with an existing, successful, app.

The most recent TV rankings comparison on MM+M from iSpot.tv includes some YouTube information from Tubular Labs. We charted out the four stats given in the article so you don't have to (no one was going to -Ed.).

Note the two axis. Views are in Millions and Engagements are in Thousands. For YouTube pre-roll and mid-roll ads that makes sense, the formats are not performance-focused. 

For the TV ads, the networks with the highest share of voice for pharma were:

Data from Statista shows EU teens (12-18) on screens for four hours weekdays and six on weekends.